Evaluation of surrogate markers and clinical outcomes in two-year follow-up of eighty-six human immunodeficiency virus-infected pediatric patients

Pediatric Infectious Disease Journal

Volumn 17, Issue 1, 1998, Pages 18-23

  Valentine, Megan E ^a   Jackson, Cynthia R ^b   Vavro, Cindy ^c   Wilfert, Catherine M ^a   Mcclernon, Daniel ^c   St Clair, Marty ^c   Katz, Samuel L ^a   McKinney Jr , Ross E ^a  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Clinical outcomes; Human immunodeficiency virus; Viral load

Indexed keywords

CD4 ANTIGEN; VIRUS RNA;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RNA ANALYSIS; SCHOOL CHILD; VIRUS LOAD;

EID: 0031908833     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199801000-00005     Document Type: Article

References (16)

1. Centers for Disease Control and Prevention. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994; 43(RR12):1-10.
2. Ho DD. Viral counts count in HIV infection. Science 1996; 272:1124-5.
3. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
4. McIntosh K, Shevitz A, Zaknun D, et al. Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus. Pediatr Infect Dis J 1996;15:1087-91.
5. Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. N Engl J Med 1997;336:1337-42.
6. Mofenson LM, Korelitz J, Meyer WA, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. J Infect Dis 1997; 175:1029-38.
7. Katzenstein TL, Pedersen C, Neilsen C, Lundgren JD, Jakobsen PH, Gerstoft J. Longitudinal serum HIV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcome. AIDS 1996;10:167-73.
8. Henrard DR, Phillips JF, Muenz LR, et al. Natural history of HIV-1 cell-free viremia. JAMA 1995;274:554-8.
9. Havlir DV, Richman DD. Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med 1996;124:984-94.
10. Jackson CR, Vavro CL, Valentine ME, et al. Effect of influenza immunization on immunologic and virologic characteristics of pediatric patients infected with human immunodeficiency virus. Pediatr Infect Dis J 197;16:200-4.
11. Urdea MA. Branched DNA signal amplification. Biotechnology 1994;12:926-7.
12. Urdea MS, Wilber JC, Yeghiazarian T, et al. Direct and quantitative detection of HIV-1 RNA in human plasma with a branched DNA signal amplification assay. AIDS 1993; 7(Suppl 2):S11-14.
13. Dewar RL, Highbarger HC, Sarmienta MD, et al. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J Infect Dis 1994;170:1172-9.
14. Van Gemen B, van der Wiel P, van Beuningen R, et al. The one-tube quantitative HIV-1 RNA NASBA: precision, accuracy, and amplification. PCR Methods Appl 1995;4:S177-84.
15. Vandamme A-M, Van Dooren S, Kok W, et al. Detection of HIV-1 RNA in plasma and serum samples using the NASBA amplification system compared to RNA-PCR. J Virol Methods 1995;52:121-32.
16. Schuurman R, Descamps D, Weverling GJ, et al. Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 1996;S4:3016-22.